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Abstract—During liver transplantation (LT) the glucose
metabolism is effected by a crucial disturbance. The blood
glucose level is extremely hard to control by conventional clinical
protocols during this phase. Model based approach can enhance
the blood glucose control during the anhepatic phase and post-
anhepatic phase. The physiological constants of validated clinical
metabolic model were slightly modified based on previous studies.
The model fitting errors and the sufficient capture of the
blood glucose (BG) dynamic evincived the applicability of the
model. However the particular/sufficient per-patient estimation
of endogenous production could more enhance the performance
of the model based BG prediction.
I. INTRODUCTION
The Liver plays an important role maintaining the glucose
metabolic balance in the organism. Nutrient rich blood,
coming from the intestines reaches first the liver through
the portal vein. Based on it’s anatomical position, besides
it’s filtering function, the liver developed to maintain the
homeostasis, ensuring a constant blood glucose metabolism
in the peripheral organs and tissues [1]. On the strength of
the blood-level, the liver can uptake glucose from the blood
for short, medium and long term storage in several form. In
post-absorptive condition, it can be considered as the main
source of the endogenous glucose production EGP.
The process of the liver transplantation can be divided into
three main phases. The first steps is the so called pre-anhepatic
phase (pre-AH), the second is the anhepatic phase (AH) and
the third is the post-anhepatic phase (post-AH) or reperfusion
step. The anhepatic phase refers to the absence of the liver.
During liver transplantation (LT), the absence of liver,
causes enormously disturbance in the maintaining function.
As a consequence the variability of the blood glucose (BG)
concentration increases during the surgery, particularly after
reperfusion phase [2] [3], it can be seen also on Fig. 2. The
appropriate management of the metabolism in these phases
towards reduction of the BG, would promote the recovery of
the liver-transplanted patients [4].
There’s a metabolic model (ICING2), which can tolerate
despite the high level inter- and intra patient variability at
intensive care unit (ICU), modeling the human metabolic
system. On the strength of previous studies [3] the ICING2
model in certain phase of the surgery (anhepatic phase and
post-anhepatic phase after reperfusion) is only able to repro-
duce the clinical measured values with particular error. In the
course of the recent study the possible necessary modifications
were analyzed in the interest of the accurate modeling of the
metabolic system during liver-transplantation.
Fig. 1. Blood glucose (BG) trends (Mean ± SE) during the surgery phases;
pre-AH (pre-anhepatic), AH (anhepatic), post-AH (post-anhepatic). The data
were obtained from several studies [5], [6], [7] (in accordance with the bar-
order, the last three without SE were obtained from the same paper), the white
face color bar represent the recent measurements. The measurements except
the first bar show a high rate of correlation.
II. METHODS
The aim of this study was to prove the applicability of a
clinical valid ICU metabolic model for liver-transplantation
(LT) settings. This section concentrates on the recently mea-
sured clinical data, the metabolic model, the researches on the
variation of physiological factors during liver transplantation
and the synthesis of the results of the methods, listed above.
A. Data
The data of 13 orthotopic liver transplanted (OLT) patients
were sampled at the Transplantation and Surgery Clinic
in Budapest. The blood glucose levels were measured
by Astrup blood gas analysis apparatus. Additionally all
insulin, glucose infusion data were recorded, just as the
times for each major surgical steps; 1) liver hepatectomy, 2)
reperfusion through the portal vein, 3) reperfusion through the
hepatic aorta. The average length of the anhepatic status was
80.4 ± 27 minutes. During the surgery a significant increase
can be discovered, which proved to be independent of the
administration of exogenous glucose or insulin [2] [3] (Fig. 2).
B. Metabolic model
The ICING2 (Intensive Control Insulin-Nutrition-Glucose)
is a clinically validated metabolic model [8]. The model
describes the function of the metabolic system, the uptake
and the release of glucose in the body. It also includes the
aspiration function of the liver to maintain the homeostasis.
The model describes the glucose release of the liver by the
endogenous glucose production EGP , and the endogenous
glucose clearance pG. The factors are listed in the Table I.
The G refers to the plasma glucose concentration, the Q to
the interstitial insulin concentration, I to the plasma insulin
concentration. The evolution of the variables are described by
the Equations (1-7).
Fig. 2. Blood Glucose level trends with IQR during LT surgery of 12 patients;
pre-AH (pre-anhepatic), AH (anhepatic), post-AH (post-anhepatic). According
to the blood glucose (BG) variability the post-anhepatic phase can be divided
in two sub-phases.
TABLE I
PHYSIOLOGICAL CONSTANTS USED IN ICING2 FOR ICU TREATMENT
[8] [9]
Model
var.
Description
Numerical
value
[typical
range]
pG Endogenous glucose clearance 0.006min−1
SI Insulin sensitivity
αG
Saturation of insulin-
dependent glucose clearance
and receptor-bound insulin
clearance from interstitium
165 LmU
d1
Rate of glucose transfer be-
tween the stomach and gut
−ln(0.5)
20
min−1
d2
Rate of glucose transfer from
the gut to the bloodstream
−ln(0.5)
100
min−1
Pmax
Maximal disposal rate from
the gut 6.11mmol/min
EGPb
Basal endogenous glucose pro-
duction (unsuppressed by glu-
cose and insulin concentration)
1.16mmol/min
CNS
Non-insulin mediated glucose
uptake by the central nervous
system
0.3mmol/L
VG Glucose distribution volume 13.3L
nI , nC
Rate of transport between
plasma and interstitial insulin
compartments
0.006 1/min
αI
Saturation of plasma insulin
clearance by the liver 1.7e− 3 L/mU
VI Insulin distribution volume 4L
xL
First-pass hepatic insulin clear-
ance
0.67−
nK
Clearance of insulin from
plasma via the renal route 0.0542 1/min
nL
Clearance of insulin from
plasma via the hepatic route 0.1578 1/min
G˙ = −pG ·G(t)− SIG(t) Q(t)
1 + αGQ(t)
+
P (t) + EGPb − CNS + PN(t)
VG
(1)
I˙ = − nLI(t)
1 + αII(t)
− nKI(t)− (I(t)−Q(t))nI
+
uex(t)
VI
+ (1− xL)uen
VI
(2)
Q˙ = (I(t)−Q(t))nI − nC Q(t)
1 + αGQ(t)
(3)
P˙1 = −d1P1 + P (t) (4)
P˙2 = −min(d2P2, Pmax) + d1P1 (5)
uen = k1e
−I(t)k2/k3 (6)
P (t) = min(d2P2, Pmax) + PN(t) (7)
C. Previous studies on liver transplantation caused
metabolism variation
A number of studies have been carried out on analyzing the
variation of glucose metabolism during liver transplantation
. The glucose levels were measured frequently, furthermore
they focused on the changes in endogenous glucose produc-
tion (using dilution methods with several tracers, or analyt-
ical methods, derivation of other quantities) and the glucose
clearance. In addition the rate of the changes in circulation,
like the glucose distribution volume (glucose space) or the
femoral blood pressure [5]. Also the concentration change
of substance-levels was recorded (sodium, potassium) [10] as
well as the hormone-levels like c-peptide, alanine, glutamine;
these concentrations also refer to the extrahepatic functions of
glucose release and uptake [5] [11] [12] [13].
In the terms of the recent study one relevant factor is
the development of blood glucose concentratio. Atchison et
al.[2] reported an intensive increase of BG level during AH-
phase and even more intensive increase after the reperfusion
rate. They proved also it’s independence of any exogenous
glucose and insulin administration. These data seem to be
consistent with the recent clinical measurements Fig. 2 and
the experiences of Tsinary et al. [6] and Kim et al. [7], only
Battezzati et al. [5] reported difference BG evolution tendency
in AH and post-AG sections.
The determination of extra-hepatic endogenous glucose pro-
duction (EGP) was followed by elevated focus of interest in
the recent time. The researches could be divided into several
subgroups; one part of the studies measured or estimated
analytical way the EGP during LT [15], the other one was
to measure the EGP by dilution method in post-absorptive
state [5] [13] [12], another group stimulated the metabolic
system by glucose and insulin clamps [11]. All of the studies
were to identify the renal contribution (Kidney) to the EGP.
The contribution of the kidney to the EGP is estimated about
25−35% in post-absorptive state [12] [13], the contibution in
anhepatic phase according to the studies counts for 50− 60%
[5] [15] of the baseline (average healthy state). The present
study uses the results, listed on the Table II and Table III.
D. Model parameter settings & Model fitting design
In the phases of the surgery, the constants describing the
metabolic function, change as described in the previous section
(Table III, EGP Glucose Space, Glucose Clearance). The
recent clinical measurements’ and other studies measurements
show a high correlation in statistical data in each surgical
phases (Fig. 1). Considering this fact, the results of the
previous researches on the topic, can be inserted in the
ICING2 model. In addition the model contains such metabolic
functions describing factors, which highly effected by the liver
function. In absence of the liver based on that fundamental
physiological considerations they can be set to zero (clearance
of insulin form plasma via the hepatic route the first pass
hepatic insulin clearance). The time-function of the data should
be also analyzed; the hepatic function, and also the metabolic
function was considered to be normal in pre-anhepatic phase
TABLE II
BLOOD GLUCOSE EVOLUTION UNDER LIVER TRANSPLANTATION,
RESULTS [MEAN+ SE] OF PREVIOUS RESEARCHES. Tsinari et al. [6]
CLASSIFIED THE PATIENTS BY THE PHYSICAL STATUS ON THE STRENGTH
OF THE RECOMMENDATION OF AMERICAN SOCIETY OF
ANESTHESIOLOGISTS (ASA)
Ref. Unit pre-AH AH post-AH
[5] mg/dl 174± 11 111.24 ± 0.26 97±10
[7] mg/dl 117.6± 32.9 153.2±39.8 NaN
ASA III [6] mg/dl 107.3 190 219.77
ASA IV [6] mg/dl 123.13 174.7 211.04
ASA V [6] mg/dl 143 143.33 209.33
TABLE III
EXTRACTED PHYSIOLOGICAL PARAMETERS, REFERRING TO THE
CHANGES DURING ANHEPATIC PHASE
Parameters Ref. unit pre-AH AH post-AH
EGP
[15]
mg
kg min
2.6 1.38 NaN
[5]
µmol
kg min
NaN 9.5 NaN
[5] % NaN 65 NaN
Glucose
space [5] % baseline 75 baseline
Glucose
clearance
[5] % baseline 75 NaN
(assumption for the renal contribution of the EGP), and already
one hour after the reperfusion, as a result, the variation of the
parameters was carried out for the anhepatic phase.
Fig. 3. The Comparison of Blood Glucose evolution of the statistical data of
the clinical measurements , ICING2 model, and the modified ICING2 model.
The figure represents the important steps of the surgery; A the pre-anhepatic
phase, B is the anhepatic phase, C regards to the post-anhepatic phase after
the reperfusion
III. RESULTS
After the modification of the original model parameters
during the anhepatic phase, the clinical measurements and the
results of the model fitting are shown on the Fig. 3.
On the basis of the main steps of the surgery, the time
of the study were divided into the following phases; A (pre-
anhepatic), B (anhepatic), C (post-anhepatic I) and D (post-
TABLE IV
MAPE (MEAN ABSOLUTE PERCENTAGE ERROR) [%] ERROR OF THE
WHOLE COHORT FOR THE CERTAIN PHASES
Phase ICING2 orig. ICING2 mod.
pre-anhepatic 5.056 0.892
anhepatic 11.901 2.939
post-anhepatic I. 7.842 1.567
post-anhepatic II. 0.541 0.553
anhepatic II). Between the phases the surgery steps were
indicated (removal of the liver, unclamping of the portal
vein). The Figure 3 represents the statistical data of clinical
measurements, as well as the simulations of whole patient
cohort. The lengths of the phases A and B at each patients are
different thus the time was normalized in these cases. During
the C and D phases the horizontal axis represents the elapsed
time in hours.
The fitting of the original ICING2 model differs from the
clinical measurements during the anhepatic time, and thus
during the approximately 10 hours after reperfusion high vari-
able interval until the normalization of the glucose metabolism
(post-anhepatic II).
As a results of the modified parameters during the B phase,
the ICING2 is able to follow the increase and the variability
of the blood glucose level dynamic (Table IV).
IV. DISCUSSION & CONCLUSION
The fitting results (Fig. 3, Table. 4.) of the modified ICING2
model denotes it’s applicability for the assistance of glucose
management during liver transplantation (LT). As the results
of the change of the physiological constants (EGP, V g)
according to the previous studies and the varying of the factors
describing the glucose metabolism (Pg, nL, uen), the fitting of
the model was able to capture the highly variable dynamic of
the blood glucose (BG) concentration also in the anhepatic
phase and the post- anhepatic phase after the reperfusion
properly.
The results of previous researches, which discovered the
changes of glucose metabolism during LT, inserted into the
ICING2 model, it is appropriate for the prediction l and thus
for the control of blood glucose (BG) level during LT, enhanc-
ing the recruitment of the patients. The recent model fitting
proves the assumption about the existence of non-hepatic EGP
(endogenous glucose production). However for the shake of
the accurate knowing of the whole glucose metabolism during
liver transplantation makes the identification of the proper
function of EGP and insulin sensitivity necessary.
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